Determinants of severity among hospitalised COVID-19 patients: Hospital-based case-control study, India, 2020.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 34965276.
- Also identified by DOI 10.1371/journal.pone.0261529 and PMC identifier 8716035.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Risk factors for the development of severe COVID-19 disease and death have been widely reported across several studies. Knowledge about the determinants of severe disease and mortality in the Indian context can guide early clinical management. We conducted a hospital-based case control study across nine sites in India to identify the determinants of severe and critical COVID-19 disease. We identified age above 60 years, duration before admission >5 days, chronic kidney disease, leucocytosis, prothrombin time > 14 sec, serum ferritin >250 ng/mL, d-dimer >0.5 ng/mL, pro-calcitonin >0.15 μg/L, fibrin degradation products >5 μg/mL, C-reactive protein >5 mg/L, lactate dehydrogenase >150 U/L, interleukin-6 >25 pg/mL, NLR ≥3, and deranged liver function, renal function and serum electrolytes as significant factors associated with severe COVID-19 disease. We have identified a set of parameters that can help in characterising severe COVID-19 cases in India. These parameters are part of routinely available investigations within Indian hospital settings, both public and private. Study findings have the potential to inform clinical management protocols and identify patients at high risk of severe outcomes at an early stage.
Medical subject headings
- COVID-19
- Hospitalization
- SARS-CoV-2
- Severity of Illness Index